chartexchange

The Precision Peptide Company Advances Needle-Free GLP-1 Tirzepatide Patch into Formal U.S. Testing

Newsfile | Oct 13, 2026 7:00 AM EDT

HighlightsFormal U.S. testing now underway for the Company's needle-free tirzepatide GLP-1 transdermal patchTargets the US$66 billion global GLP-1 market, projected to reach US$185.3 billion by 2033²,³Existing tirzepatide products delivered by needle injection generated US$36.5 billion in 2025¹~11% of U.S. adults now use GLP-1 medications, nearly quadruple the rate in 2024⁴Testing is being conducted in the United States through the Company's domestic product-development infrastructureVancouver,...

Read original article